Thank you for Subscribing to Life Science Review Weekly Brief
×
Life Science Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review
Top 10 Cancer Immunotherapy Solutions Companies – 2022
I mmunotherapy or the use of the body’s immune system to fight cancer, has gained immense traction in the past few years. It ensures long-term cancer protection with fewer side effects across different cancer types, including melanoma, prostate cancer, and breast cancer, to name a few. The success and wide adoption of immunotherapy have contributed to the growth of this market. According to reports, the cancer immunotherapy market is expected to grow at a CAGR of 13.8 percent from 2018 to 2024 to reach $152.83 billion by 2024. Several innovative start-ups are also entering this field, and the research works have witnessed tremendous acceleration.
Most of these researches are dedicated to finding ways to boost the immune system. For example, several works are being conducted in the fields of Chimeric antigen receptor (CAR) T-cell therapy and Tumor-infiltrating lymphocytes and interleukin-2 (IL-2). Also, till now, the success of immunotherapy has been restricted to the field of liquid tumors; patients with solid tumors were never able to reap the benefits of this advanced treatment method. Research work in this specific area has also been accelerated.
With all these advancements, it won’t be an overstatement that the cancer immunotherapy space will gain significant traction in the coming years and several innovative and novel treatment methods will surface. But the efficacy of these processes will be proved only after proper pre-clinical and clinical studies.
In this edition, our aim is to make readers acquainted with the recent developments in the cancer immunotherapy field to help them understand the market and research trends.
Let us know your thoughts.
Nominate a Company
Our subscribers nominate the companies with whom they have collaborated and gotten results. If you think there is a company that deserves to be on our upcoming prestigious annual list of Top 10 Cancer Immunotherapy Solutions Companies – 2022 , please write to us about them and the reasons you think they need to be on the list
-
SIRPantImmunotherapeutics is unique in the cellular immunotherapy space in that SIRPant-M™ is cancer agnostic, not requiring any genetic modification to target specific cancer markers such as HER-2. SIRPant-M™ targets all newly presented cancer antigens and has demonstrated the ability to phagocytize a wide array of cancer cell types.
Most of our pre-clinical work utilized syngeneic solid tumor models involving some of the most difficult to treat cancer cell lines, such as MC38 colorectal carcinoma, KPC pancreatic ductal adenocarcinoma, and LLC non-small cell lung carcinoma
—Robert J. Towarnicki Sr., President and CEO
SIRPant Immunotherapeutics
Management
Robert J. Towarnicki Sr., President and CEO
-
The company provides BiXAb, a bi-specific platform designed to facilitate faster and cost-effective development of bi- and multi-specific antibodies for cancer treatment. BiXAb® generates bi-specific antibodies that are bi-valent for each target, and breakthrough T Cell engagers or other suitable mechanisms of action.
Pierre-Emmanuel Gerard, CEO and FounderBiXAb essentially opens a gateway to forge novel approaches of T cell engagers
-
MedOnect Therapeutics, Inc., provider of technology based therapeutic treatments to defy cancer, opioids, and infectious diseases, came up with a renewed scientific understanding about cancerous cells and their spread in the body. After long intensified research, MedOnect invented an innovative blood cancer therapy for the patients with a different scientific approach.
Our job is not to compete but to complete the process of cancer therapy by enabling patients to avail treatment at their homes
—Dr. Ziad George, Executive Manager of MedOncet
-
Sino Biological is an internationally-recognized reagent supplier and contract research organization, aiding researchers and pharmaceutical companies worldwide especially in cancer and immunotherapy research. Headquartered in Beijing with subsidiaries in the United States, Germany, and Japan, Sino Biological manufactures recombinant proteins, antibodies, ELISA kits, and cDNA clones in large quantities according to the requirements of its clients.
With proprietary expression platforms and high-throughput and scale-up capabilities, Sino Biological can successfully develop reagents targeting cancer immunotherapy, no matter how difficult the project is
—Dr. Rob Burgess, Chief Business Officer, Sino Biological.
Sino Biological
Management
Dr. Rob Burgess, Chief Business Officer, Sino Biological.
-
entrinsic bioscience
entrinsic bioscience (EBS) is a developer of a bio mapping and electrophysiology platform designed to discover novel biocatalysts with transformational health benefits. The company's platform harnesses the body's own communication and natural protein regulation system to selectively modulate proteins, enabling patients to get relief from the side effects caused by chemotherapy or radiation therapy.
-
Amgen
Amgen is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
-
Incyte Corporation
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. The company’s unique expertise in medicinal chemistry and biology has enabled them to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. Incyte is advancing a growing pipeline of medicines across Oncology and Inflammation & Autoimmunity.
-
INmune Bio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease coverage. Express Courier offers e-commerce solutions, same-day, scheduled and on-demand distribution, as well as warehousing logistics to support businesses of all sizes.
-
Istari Oncology
Istari Oncology is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy and driving execution while seeking opportunities for partnership and collaboration with the world’s leading cancer centers and oncology biotech firms.
-
Marengo Therapeutics
Marengo Therapeutics is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. The company’s unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.
